FDA Adverse Event Malfunction Summary report: N

OMNIPOD INSULIN PUMP

MDR report key: 8437732 · Received March 20, 2019

Report

Report Number
3004464228-2019-02236
Event Type
Malfunction
Date Received
March 20, 2019
Date of Event
February 25, 2019
Report Date
February 25, 2019
Manufacturer
INSULET CORPORATION
Product Code
LZG
PMA / PMN Number
K122953
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
MA, US
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 1

THE RETURNED DEVICE WAS EVALUATED AND NO KINKS OR BENDS WERE IDENTIFIED ON THE EXPOSED PORTION OF THE CANNULA. FLUID PATH TESTING SHOWED THAT INSULIN WAS ABLE TO PASS OUT THE DISTAL TIP OF THE SOFT CANNULA. NO OTHER DEFECTS OR DEFICIENCIES WERE IDENTIFIED DURING THE INVESTIGATION.

Additional Manufacturer Narrative · 1

THE PRODUCT WAS NOT RETURNED FOR EVALUATION. WE ARE UNABLE TO CONFIRM THE REPORTED BENT CANNULA OR TO DETERMINE WHETHER IT CONTRIBUTED TO THE REPORTED HYPERGLYCEMIA. LOT RELEASE RECORDS WERE REVIEWED AND THE PRODUCT LOT MET ALL ACCEPTANCE CRITERIA. OMNIPOD INSULIN MANAGEMENT SYSTEM ¿ USER GUIDE. MODEL: CAT45E/CAT45F. 15546-AW REV D 06/2016. CHECKING YOUR BLOOD GLUCOSE 7 / PAGE 98. WARNING: IF YOU GET RESULTS BELOW 3.9 MMOL/L OR ABOVE 13.9 MMOL/L, BUT DO NOT HAVE SYMPTOMS OF HYPOGLYCEMIA OR HYPERGLYCEMIA REPEAT THE TEST. IF YOU HAVE SYMPTOMS OR CONTINUE TO GET RESULTS THAT FALL BELOW 3.9 MMOL/L OR ABOVE 13.9 MMOL/L, FOLLOW THE TREATMENT ADVICE OF YOUR HEALTHCARE PROVIDER.

Description of Event or Problem · 1

IT WAS REPORTED THE PATIENT¿S BLOOD GLUCOSE REACHED BETWEEN 14, 19 TO 20 MMOL/L (252, 342 TO 360 MG/DL) AND THAT THE CANNULA WAS BENT. HYPERGLYCEMIA TREATED BY PATIENT WITH A CORRECTION BOLUS AND ACTIVATING NEW POD. INSULIN WAS LEAKING AT THE INSERTION SITE AND THAT THE ADHESIVE PAD WAS WET. THE POD WAS WORN BETWEEN 36 AND 48 HOURS ON THE LEG.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
229412 OMNIPOD INSULIN PUMP PUMP, INFUSION, INSULIN LZG INSULET CORPORATION 15880 L44200

Patients

Seq Age Sex Outcome Treatment
1 18 YR